Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity explicitly. The company has a strong net cash positive balance sheet with approximately INR600 crores of net cash. This healthy balance sheet positions Medanta well to fund future expansion plans and growth internally without the need for immediate external fundraising. Medanta's growth and capex plans, such as expansions in Lucknow, Patna, Noida, and the DLF partnership, are expected to be funded through internal accruals and existing cash resources. No explicit mention of fundraising via debt or

Any current/future capex/capital investment/strategic investment?

Medanta plans significant capex over the next three years, estimated at INR 1,000-1,100 crores, primarily for expansions in Lucknow, Patna, Noida, and maintenance. Lucknow capacity to increase from 601 to about 950 beds with related capex. Patna to expand capacity to nearly 650 beds, including around 50 ICU beds due to high demand for critical care. Noida hospital is a 550-bed facility, with 300 beds in the initial phase; capex incurred includes INR 308 million in H1 FY ‘24. Gurgaon expects limited capex mainly for interior fit-outs for ~100 bed additions, plus INR 70-100 crores over next year

Future growth expectations in sales/revenue/volumes?

Strong volume growth driven by higher patient footfalls across all hospital units (Q2 FY ’24 inpatient volumes up 19.4% YoY). Continued bed additions planned: 125–150 beds in Lucknow and ~50 beds in Patna by end of current fiscal year. Expansions at Patna and Lucknow progressing well, with focus on critical care infrastructure. New hospital projects underway: Noida expected to commence operations by FY ’25 end; Medanta Delhi Hospital (DLF JV) progressing. Addition of 250+ doctors in H1 FY ’24 supporting volume and service growth. Higher occupancies sustained with mature cluster occupancy aroun

Future growth expectations in earnings/operating earnings/profits/EPS?

Medanta expects continued strong growth driven by both mature and developing hospital clusters. Developing hospitals like Lucknow and Patna are expanding bed capacity and clinical talent, supporting revenue and EBITDA growth. Patna’s profitability has significantly improved and is expected to contribute more as PPP patient inflows rise. Mature hospitals like Gurgaon show higher occupancy and improved margins, benefiting from added clinical talent and equipment utilization. Operating leverage is expected to improve margins as fixed costs do not scale linearly with increased volumes. Tariff incr

Global HealthQ2 FY24Healthcare Services

Global Health Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,357P/E: 70.2Market Cap: ₹40.2K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Strong volume growth driven by higher patient footfalls across all hospital units (Q2 FY ’24 inpatient volumes up 19.4% YoY).
Continued bed additions planned: 125–150 beds in Lucknow and ~50 beds in Patna by end of current fiscal year.
Expansions at Patna and Lucknow progressing well, with focus on critical care infrastructure.
New hospital projects underway: Noida expected to commence operations by FY ’25 end; Medanta Delhi Hospital (DLF JV) progressing.
Addition of 250+ doctors in H1 FY ’24 supporting volume and service growth.
Higher occupancies sustained with mature cluster occupancy around 65%.
Focus on tariff increases in developing hospitals (Patna, Lucknow) to improve ARPOB in medium term.
Operating leverage benefits expected as facilities scale, improving margins alongside volume growth.

Margin guidance

Category 3

Medanta expects continued strong growth driven by both mature and developing hospital clusters.
Developing hospitals like Lucknow and Patna are expanding bed capacity and clinical talent, supporting revenue and EBITDA growth.
Patna’s profitability has significantly improved and is expected to contribute more as PPP patient inflows rise.
Mature hospitals like Gurgaon show higher occupancy and improved margins, benefiting from added clinical talent and equipment utilization.
Operating leverage is expected to improve margins as fixed costs do not scale linearly with increased volumes.
Tariff increases are anticipated in developing hospitals, positively impacting earnings.
Noida hospital project is on track, poised to add to future revenues from FY25 onwards.
Overall, the company aims for a longer-term approach focusing on quality, ethics, and sustainable growth, with steady margin expansions and volume increases leading to higher profits and EPS.

See what Global Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity explicitly.
The company has a strong net cash positive balance sheet with approximately INR600 crores of net cash.
This healthy balance sheet positions Medanta well to fund future expansion plans and growth internally without the need for immediate external fundraising.
Medanta's growth and capex plans, such as expansions in Lucknow, Patna, Noida, and the DLF partnership, are expected to be funded through internal accruals and existing cash resources.
No explicit mention of fundraising via debt or equity was made during the call or in the provided pages.

Order book

The transcript provided does not explicitly mention current or expected order book or pending orders for Medanta – Global Health Limited. However, relevant information on expansions and projects includes: - Ongoing bed expansions at Lucknow (additional 125-150 beds) and Patna (approximately 50 beds) underway. - Noida Hospital project progressing well, expected to commence operations by FY ‘25 end. - Medanta Delhi Hospital partnership with DLF is on track with the definitive agreement executed. - Capex of INR 1,276 million in H1 FY ‘24, including INR 308 million toward Noida Hospital. - Focus on adding clinical talent and facility expansions to support growth. - Strong pipeline of projects and investments indicate potential growth in order book in healthcare infrastructure and services. No direct quantitative data on order book or pending orders was detailed in the call transcript.

See what Global Health management said on order book — free account, 30 seconds.

Capex plans

Yes

Medanta plans significant capex over the next three years, estimated at INR 1,000-1,100 crores, primarily for expansions in Lucknow, Patna, Noida, and maintenance.
Lucknow capacity to increase from 601 to about 950 beds with related capex.
Patna to expand capacity to nearly 650 beds, including around 50 ICU beds due to high demand for critical care.
Noida hospital is a 550-bed facility, with 300 beds in the initial phase; capex incurred includes INR 308 million in H1 FY ‘24.
Gurgaon expects limited capex mainly for interior fit-outs for ~100 bed additions, plus INR 70-100 crores over next year for medical equipment upgrades.
Maintenance capex for mature units likely around INR 60-75 crores annually.
Funding is supported by a strong net cash positive balance sheet (~INR 600 crores net cash).
Strategic partnerships include the joint venture with DLF and exploration of greenfield and O&M models for expansion in central India and the NCR region.

Track Global Health — get its next earnings analysis in your feed

How does Global Health rank vs peers in Healthcare Services?

Pro feature

ThisGlobal Health

Rev 2Mar 3

See where Global Health sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Global Health rank in Healthcare Services?

Compare Global Health against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Global Health's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →